DEEP RESEARCH · RemeGen · AbbVie RC148 License + LigaChem Biosciences Comparison

RemeGen and RC148: The Essence of a $5.6B Mega-Deal and the Competitive Edge of PD-1/VEGF Bispecifics

Strategic implications of the AbbVie–RemeGen license · vs. Ivonescimab · LigaChem (ADC) vs. RemeGen (BsAb) technology convergence

Date: 2026-01-14 · Global oncology / bispecific antibody analysis · Gemini-assisted draft

0. Bottom line first

Interpretation: LigaChem Biosciences (ADC, "precision missile") and RemeGen (bispecific, "TME redesign") are not rivals but two pieces of one convergence puzzle. The market is moving from single-drug efficacy battles toward "ADC + bispecific" combination wars.

1. Deal analysis

1.1 Structure and financial impact

Official fact: AbbVie acquires exclusive global development, manufacturing, and commercialization rights to RC148 outside Greater China (mainland, HK, Macau, Taiwan). $650M non-refundable upfront, up to $4.95B in milestones, double-digit net-sales royalty. Total deal value ~$5.6B.

Interpretation: Against a 2024-end cash-burn concern, $650M (≈ RMB 4.7B) equals ~3 years of annual R&D — a financial cushion enabling clinical acceleration without further dilution.

1.2 AbbVie's strategic calculus — why RC148?

1. Next-gen IO leadership: Ivonescimab proved PD-1/VEGF bispecific superiority over Keytruda in Phase 3 NSCLC (HR 0.51) — signaling a "game-changer" modality. With Humira's patent cliff behind it, AbbVie needs new growth.
2. Internal ADC synergy: Combination potential with AbbVie's ADC portfolio (Elahere etc.). VP Oncology Daejin Abidoye explicitly highlighted "RC148 + AbbVie ADC combination opportunities" in the press release.

Official fact: VEGF blockade normalizes tortuous tumor vasculature, lowering interstitial fluid pressure and enabling large-molecule ADCs to penetrate deeper. Simultaneous PD-1 blockade activates T cells — an ideal pairing for ADC + immune synergy.

2. RC148 technical deep dive

2.1 Mechanism of action — redesigning the TME

1. Dual blockade: One arm blocks PD-1 (releases the T-cell brake); the other neutralizes VEGF (cuts off the tumor's supply line).
2. TME remodeling: VEGF blockade normalizes vasculature, letting activated T cells penetrate tumor interior.
3. Fc silencing: Fc-domain mutations eliminate unwanted ADCP/ADCC responses → less off-target toxicity in normal tissue.

2.2 HiBody platform and structural differentiation vs. Ivonescimab

Interpretation: RC148 was selected not just for efficacy but for "ADC-combination-optimized safety + manufacturing edge + clinical flexibility." After the first wave (Ivonescimab), it is positioned for the second wave around "ADC combinations."

3. RemeGen corporate analysis

3.1 Pipeline — not a one-hit wonder

1. Telitacicept (RC18): World-first BLyS/APRIL dual-target fusion protein. Already approved in China for SLE/RA. Globally licensed to U.S. Vor Bio ($125M+ upfront). EMA orphan-drug designation for myasthenia gravis.
2. Disitamab Vedotin (RC48): First indigenous Chinese HER2 ADC. Licensed to Pfizer/Seagen for ~$2.4B. At ESMO 2025, first-line urothelial cancer showed OS 31.5 vs 16.9 months (chemo).
3. RC28: VEGF/FGF dual-target ophthalmic fusion. China ophthalmic rights licensed to Santen.

Interpretation: Global partnerships across autoimmune (RC18), oncology (RC48, RC148), and ophthalmology (RC28) prove that HiBody, ADC, and fusion-protein platforms work as sustainable drug-discovery engines — not isolated wins.

3.2 Financial turnaround

Official fact: R&D spending rose from RMB 0.98bn (2022) to 1.31bn (2023) to 1.54bn (2024). 1H 2024 cash on hand ~RMB 0.67bn raised funding concerns.

Official fact: 2024 operating cash outflow ~RMB 1.17bn. June 30, 2025 cash ~RMB 1.27bn. Total borrowings ~RMB 2.6bn (short-term debt ~RMB 1.78bn).

Interpretation: The $650M upfront (~RMB 4.7bn) equals ~3 years of R&D — likely deployed to short-term debt + follow-on pipeline acceleration. JPMorgan and others upgraded RemeGen to Overweight.

4. Why $5.6B — anatomy of a mega-deal

4.1 Factor 1: The "Ivonescimab shock" (Validation Premium)

Official fact: May 2024 Akeso Ivonescimab HARMONi-2 Phase 3 NSCLC — PFS 11.14 vs 5.82 months for Keytruda (HR 0.51, 49% risk reduction).

Interpretation: Once "PD-1/VEGF bispecifics can beat Keytruda" was proven, big pharma fell into "post-Keytruda" FOMO. RC148, one of the few validated alternatives left, inherited Ivonescimab's pricing power.

4.2 Factor 2: AbbVie ADC synergy (Multiplier)

AbbVie has been aggressively investing in ADCs (e.g., $10.1B ImmunoGen acquisition). RC148 pairs ideally with telisotuzumab adizutecan etc. VEGF normalization → better ADC delivery + PD-1 activation → expanded systemic immune response from ADC-induced cell death. AbbVie is betting on the multiplier effect on its entire ADC portfolio, not a single drug.

4.3 Factor 3: Scarcity Premium

PD-1/VEGF bispecifics are hard to develop (tricky binding balance). Global-stage assets: Ivonescimab, BNT327 (BioNTech/BMS), RC148. With BioNTech/BMS partnered, RC148 was essentially the only big-pharma-available asset — supplier-favored market giving RemeGen leverage.

5. [Appendix] LigaChem Biosciences vs RemeGen — ADC vs Bispecific

5.1 LigaChem Biosciences: "ConjuAll™" platform

Three core elements of the ConjuAll™ ADC platform:

1. Site-specific conjugation: CAAX motif at antibody C-terminus + farnesyltransferase → uniform DAR exactly 2 or 4. Higher serum stability and CMC efficiency.
2. Beta-glucuronide linker: Stable in plasma, specifically cleaved by lysosomal β-glucuronidase in tumor cells — minimizes off-target toxicity, maximizes tumor-cell release efficiency.
3. PBD prodrug payload: Potent DNA-binding payload attached as prodrug → activated only inside tumor cells, widening the therapeutic index.

Official fact: Cumulative deal value KRW 8tn+. Janssen LCB84 (Trop2-ADC) total $1.7B (upfront $100M+, option fee $200M). Amgen 5-target platform deal up to $1.25B.

5.2 Technical contrast — "missile" vs "engineer corps"

5.3 Comparative superiority

6. Competitive landscape and risks

6.1 PD-1/VEGF bispecific competitors

• Ivonescimab (Akeso/Summit): Leader, demonstrated Keytruda superiority in global Phase 3. Closest to U.S. FDA approval.
• BNT327 (BioNTech/BMS): BioNTech-acquired Biotheus pipeline. Strong efficacy, rapidly emerging.
• LM-299 (Merck/LaNova): Merck's defensive card despite Keytruda cannibalization risk.

6.2 Risk factors

1. Data replication: Will early positive data hold in global Phase 3? Race/SoC differences are variables.
2. Safety: VEGF-inhibitor side effects (hypertension, bleeding, proteinuria) + ADC toxicity require careful management in combination.
3. Geopolitics: Biosecure Act and U.S.-China tensions. Mitigated since AbbVie holds global rights and runs development.
4. Balance sheet: RemeGen total debt ~RMB 2.6bn (ST ~1.78bn) vs cash RMB 1.27bn (June 2025). The upfront eases this materially.

7. Milestones and conclusion

7.1 Key catalysts (next 2–3 years)

• RC148 global trials kicked off by AbbVie + telisotuzumab adizutecan combination data.
• RC48 Pfizer/Seagen global Phase 3 urothelial cancer readout (2025–2026).
• RC18 (Telitacicept) Vor Bio global Phase 3 for SLE / myasthenia gravis.

7.2 Conclusion — an ideal marriage of technology and capital

LigaChem and RemeGen are not rivals but two pieces of the next-generation oncology puzzle. LigaChem's ADC is the sharpest spear; RemeGen's bispecific is the strategist clearing the way. Markets will increasingly compete on "ADC + bispecific" combinations.